Axa Decreases Position in Acceleron Pharma Inc (XLRN)

Axa trimmed its position in shares of Acceleron Pharma Inc (NASDAQ:XLRN) by 16.8% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 269,092 shares of the biopharmaceutical company’s stock after selling 54,463 shares during the period. Axa owned about 0.59% of Acceleron Pharma worth $10,043,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in XLRN. Quantbot Technologies LP raised its holdings in shares of Acceleron Pharma by 416.3% during the 3rd quarter. Quantbot Technologies LP now owns 2,917 shares of the biopharmaceutical company’s stock valued at $108,000 after buying an additional 2,352 shares in the last quarter. BNP Paribas Arbitrage SA increased its stake in Acceleron Pharma by 969.9% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 3,627 shares of the biopharmaceutical company’s stock worth $110,000 after purchasing an additional 3,288 shares during the period. Oppenheimer & Co. Inc. purchased a new position in Acceleron Pharma in the 3rd quarter worth approximately $225,000. PNC Financial Services Group Inc. increased its stake in Acceleron Pharma by 57.8% in the 2nd quarter. PNC Financial Services Group Inc. now owns 8,460 shares of the biopharmaceutical company’s stock worth $258,000 after purchasing an additional 3,100 shares during the period. Finally, Trexquant Investment LP purchased a new position in Acceleron Pharma in the 3rd quarter worth approximately $266,000. 85.70% of the stock is currently owned by institutional investors.

Shares of Acceleron Pharma Inc (NASDAQ:XLRN) opened at $41.68 on Friday. Acceleron Pharma Inc has a 1 year low of $23.07 and a 1 year high of $42.81.

Acceleron Pharma (NASDAQ:XLRN) last issued its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.67) by $0.02. The firm had revenue of $3.00 million for the quarter, compared to analyst estimates of $3.52 million. Acceleron Pharma had a negative return on equity of 40.70% and a negative net margin of 759.34%. The business’s quarterly revenue was up .0% compared to the same quarter last year. During the same period last year, the company earned ($0.55) EPS. equities analysts predict that Acceleron Pharma Inc will post -2.65 EPS for the current fiscal year.

In other Acceleron Pharma news, major shareholder Corp /De/ Celgene acquired 745,592 shares of the business’s stock in a transaction dated Monday, September 25th. The shares were purchased at an average cost of $37.00 per share, for a total transaction of $27,586,904.00. Following the transaction, the insider now owns 6,118,479 shares in the company, valued at $226,383,723. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Jean George sold 105,122 shares of Acceleron Pharma stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $35.73, for a total value of $3,756,009.06. Following the completion of the sale, the director now owns 1,250 shares in the company, valued at $44,662.50. The disclosure for this sale can be found here. 3.90% of the stock is currently owned by company insiders.

A number of brokerages have commented on XLRN. Oppenheimer reaffirmed a “hold” rating on shares of Acceleron Pharma in a research note on Monday, December 11th. HC Wainwright reaffirmed a “buy” rating and issued a $62.00 price target on shares of Acceleron Pharma in a research note on Monday, December 11th. Royal Bank of Canada began coverage on Acceleron Pharma in a research note on Thursday, September 14th. They issued a “sector perform” rating and a $44.00 price target on the stock. Cann reaffirmed a “hold” rating on shares of Acceleron Pharma in a research note on Tuesday, September 5th. Finally, UBS reaffirmed a “buy” rating and issued a $50.00 price target (up from $36.00) on shares of Acceleron Pharma in a research note on Tuesday, September 12th. Two analysts have rated the stock with a sell rating, six have issued a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. Acceleron Pharma has a consensus rating of “Buy” and an average target price of $44.56.

ILLEGAL ACTIVITY WARNING: This article was first posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this article on another domain, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this article can be read at https://www.com-unik.info/2017/12/22/axa-decreases-position-in-acceleron-pharma-inc-xlrn.html.

Acceleron Pharma Profile

Acceleron Pharma Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily.

Institutional Ownership by Quarter for Acceleron Pharma (NASDAQ:XLRN)

What are top analysts saying about Acceleron Pharma? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Acceleron Pharma and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit